Cutaneous melanoma remains the most lethal of the primary cutaneous neoplasms, and
although the incidence of primary melanoma continues to rise, the mortality from metastatic …

Genetic alterations affecting RAS proteins are commonly found in human cancers. Roughly
a fourth of melanoma patients carry activating NRAS mutations, rendering this malignancy …

Background Sinonasal neoplasms, whether benign and malignant, pose a significant
challenge to clinicians and represent a model area for multidisciplinary collaboration in …

Immune checkpoint inhibitors (ICIs), including CTLA-4-and PD-1-blocking antibodies, can
have profound effects on tumor immune cell infiltration that have not been consistent in …

Background Patients with cancer benefit from treatment with immune checkpoint inhibitors
(ICIs), and those with an inflamed tumor microenvironment (TME) and/or high tumor …

Abstract Purpose of Review Summarize the writings published in the last years on the
management and novel therapies of mucosal melanoma (MM). Recent Findings New …

Background Recent reports suggest the limited efficacy of immune checkpoints inhibitors in
advanced acral melanoma (AM). This study aims to investigate the clinical outcomes of …

Melanoma is the deadliest cutaneous cancer. Activating mutations in NRAS are found in
20% of melanomas. NRAS-mutant melanoma is more aggressive and, therefore, has poorer …

The incidence of melanoma is increasing and prolonged exposure to ultraviolet (UV)
radiation remains the main risk factor. Public health measures have been vital in tackling the …

Objectives Sinonasal mucosal melanoma (SNMM) is an extremely rare and challenging
sinonasal malignancy with a poor prognosis. Standard treatment involves complete surgical …